Endocrine Abstracts

Introduction: Obesity is one of the most prevalent health problems in our society. The marketing of Liraglutide and the Naltrexone/Bupropion combination has been given the green light.

Objectives: To analyze the differences in a series of 19 patients assigned to treatment with Liraglutide or Naltrexone/Bupropion.

Material and methods: A descriptive analysis was carried out using Stata. 19 patients were included, 9 were treated with Liraglutide and 10 with Naltrexone/Bupropion. We analyzed the percentage of weight loss and side effects at one month and two months after treatment initiation.

Results: Of the 9 patients included in the Liraglutide arm, 2 were male and 7 were female, with a mean age of 56.22 and a mean BMI of 41.35. From the Naltrexone/Bupropion group, 5 male and 5 female participants, with a mean age of 52.90 and an initial BMI of 34.40. After one month of treatment, a % weight loss of 3.81 was observed for the Liraglutide group versus 1.06 for Naltrexone/Bupropion (difference of means 2.75). After two months, a 7.51% weight loss was observed for Liraglutide versus 0.12% for Naltrexone/Bupropion (mean difference 7.40), the latter being statistically significant. 77.8% of patients treated with Liraglutide developed secondary side effects at the first month (28.57% at the second visit), only one patient withdrew from taking the drug. In the Naltrexone/Bupropion group, side effects were observed in 20% with two dropouts for this reason (another 4 abandoned the treatment for other reasons). Regarding the dosage of Liraglutide per month, 11% of Liraglutide 1.2 mg, 33% 1.8 mg, 33% 2.4 mg, 22% 3 mg. At two months, 43.86% 1.8 mg and 57.14% 3 mg.

Conclusions: In our clinical practice we observed a greater weight loss % in the Liraglutide group, especially at two months of treatment. The number of negative side effects was greater for Liraglutide, primarily in the first month, with a higher abandonment rate for Naltrexone/Bupropion.